Plasma NT‑proBNP and the extent of coronary artery disease
Association of Plasma N-terminal Pro-Brain Natriuretic Peptide Levels With the Burden of Coronary Artery Disease: Insights From a Real-World Cohort
This project tests whether a blood NT‑proBNP level can indicate how much coronary artery disease someone referred for elective coronary angiography has.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Ospedale San Raffaele Academic / other |
| Locations | 2 sites (Milan, Italy and 1 other locations) |
| Trial ID | NCT07013344 on ClinicalTrials.gov |
What this trial studies
Investigators prospectively measured plasma NT‑proBNP in consecutive adults referred for elective diagnostic coronary angiography over a two‑year period. They compared NT‑proBNP levels with the presence, extent, and severity of coronary stenoses found on angiography. Patients with conditions known to raise NT‑proBNP—heart failure, severe valvular disease, atrial fibrillation, severe CKD (eGFR <30 mL/min), prior CABG, or age over 80—were excluded to reduce confounding. NT‑proBNP was measured during hospitalization before or around the time of angiography to link biomarker levels with angiographic burden.
Who should consider this trial
Good fit: Adults under 80 referred for elective coronary angiography for suspected CAD who can have NT‑proBNP measured and do not have heart failure, severe valve disease, atrial fibrillation, severe CKD, or prior CABG.
Not a fit: Patients with heart failure, atrial fibrillation, severe valvular disease, severe chronic kidney disease (eGFR <30 mL/min), prior CABG, or age over 80 are excluded and unlikely to benefit from the study's findings because these conditions markedly affect NT‑proBNP levels or angiographic interpretation.
Why it matters
Potential benefit: If successful, NT‑proBNP measurement could help identify patients with a higher burden of coronary artery disease and help prioritize diagnostic or treatment pathways.
How similar studies have performed: Previous research has linked NT‑proBNP to overall cardiovascular risk and sometimes to coronary disease severity, but results are mixed and its specific use to estimate angiographic CAD burden is not yet established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient referred for elective coronary angiography due to suspected CAD. * NT-proBNP measurement during hospitalization Exclusion Criteria: * heart failure * severe valvular disease * atrial fibrillation * severe chronic kidney disease (eGFR \< 30 mL/min) * prior coronary artery bypass grafting * age over 80 years
Where this trial is running
Milan, Italy and 1 other locations
- IRCCS San Raffaele Hospital — Milan, Italy, Italy (Completed)
- IRCCS San Raffaele Hospital — Milan, Italy, Italy (Recruiting)
Study contacts
- Study coordinator: Carlo Gaspardone
- Email: gaspardone.carlo@hsr.it
- Phone: +393389920314
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.